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The FIP1L1-PDGFRA fusion gene is an important oncogenic driver
of chronic eosinophilic leukemia, now referred to as the WHO
subcategory ‘myeloid and lymphoid neoplasms with eosinophilia
and abnormalities of PDGFRA, PDGFRB or FGFR1′.1,2 The FIP1L1–
PDGFRA fusion is generated by a 800-kb chromosomal deletion,
unlike the majority of other fusion genes that are generated by
chromosomal translocations. The resulting FIP1L1–PDGFRα pro-
tein (Figure 1a) is a constitutive active tyrosine kinase that is highly
sensitive to the kinase inhibitor imatinib, and treatment with this
drug results in rapid complete remission for FIP1L1–PDGFRA
positive patients.3 Although the response to imatinib is excellent,
most patients require life-long treatment and the development of
resistance has been described in some cases.1,4,5
Most of our insight into the mechanism of activation of the
FIP1L1–PDGFRα kinase, its downstream signaling and its sensitiv-
ity to kinase inhibitors has been obtained from studies using
ectopic overexpression of the recombinant fusion protein in Ba/F3
cells or other cell lines such as HEK293T. The interleukin-3 (IL-3)-
dependent Ba/F3 cell line has been widely used to study
oncogenic tyrosine kinases, since many constitutively activated
tyrosine kinases can transform the Ba/F3 cells to IL-3-independent
growth.1,6,7 It is at present unknown if the data obtained from
such overexpression experiments is completely valid and if it
accurately resembles the actual situation in the leukemia cells in
which there is only one copy of the FIP1L1–PDGFRA gene driven
by the FIP1L1 promoter.
To address this question, we used CRISPR/Cas genome editing
to generate the Fip1l1–Pdgfra fusion gene by inducing a 600-kb
interstitial chromosomal deletion in the Ba/F3 cell line.8 We
designed six different guide RNAs (gRNAs) targeting exons 9, 10,
11 or 12 of Fip1l1 and three different gRNAs targeting exon 12 of
Pdgfra, reflecting similar breakpoints found in FIP1L1–PDGFRA
positive patients1 (Figure 1b). The design tool developed by the
Zhang lab (crispr.mit.edu) was used to find gRNAs with minimal
off-target effects.9 gRNA sequences were cloned into a plasmid
(pX330) carrying a Cas9 expression cassette, and this plasmid was
delivered into Ba/F3 cells by electroporation. The targeting
efficiency of the individual gRNAs in Ba/F3 cells was determined
using next-generation sequencing. Using the same strategy, the
frequency of insertions/deletions was determined for the top-4
genomic off-target locations as predicted by the design tool.
Typically, we observed an on-target targeting efficiency between 8
and 55%, while for off-target locations the observed indel
frequency was below 0.005% (Figure 1c).
To generate various Fip1l1–Pdgfra fusion genes (designated FP1 to
FP6), we combined a gRNA targeting an exon of Fip1l1 with a gRNA
targeting exon 12 of Pdgfra. Upon IL-3 removal, only Ba/F3 cells that
had generated an oncogenic Fip1l1–Pdgfrα fusion protein were able
to survive and proliferate in the absence of IL-3 (Figure 1d). The
presence of the fusion gene and protein was confirmed by PCR and
western blotting, respectively (Figures 1e and f).
Single cell clones were generated from the Ba/F3 cells
harboring the six different Fip1l1–Pdgfra fusions using semi-solid
growth medium (Clonacell, Stem Cell Technologies, Vancouver,
BC, Canada). The region spanning the fusion between Fip1l1 and
Pdgfra was amplified by PCR and sequenced using Sanger
sequencing (Figure 1g). Fluorescence in situ hybridization (FISH)
confirmed the presence of the deletion between Fip1l1 and Pdgfra
on one copy of mouse chromosome 5 and we consistently only
observed heterozygous deletions (Figure 1h). These data confirm
that the Fip1l1–Pdgfra fusion gene can be generated by CRISPR/
Cas genome editing and that expression of the fusion gene is
sufficient to transform Ba/F3 cells in a similar manner to ectopic
overexpression of the recombinant FIP1L1–PDGFRA fusion.
We showed previously that the Fip1l1 portion of the Fip1l1–
Pdgfrα fusion protein is dispensable for its transforming
capacities.10 We have to note, however, that this was only studied
under overexpression conditions.10 Using the genome editing
strategy, we now generated a fusion between Fip1l1 exon 1 and
Pdgfra exon 12 (designated FP7), using gRNAs F7+P3 (Figure 1b).
This strategy generated a fusion protein, as shown in Figure 2a,
which was able to transform the cells, confirming that also with
normal expression levels, the Fip1l1 part is dispensable for
constitutive kinase activation (Figures 2b–d).
We also showed previously that disruption of the juxtamem-
brane domain of Pdgfra (exon 12), removing one of the conserved
tryptophan residues responsible for autoinhibition of the JM
domain, is absolutely required for the transforming capacities of
the fusion protein.10 To confirm these earlier findings with more
normal expression levels, we used the same genome editing
strategy to generate a Fip1l1–Pdgfrα fusion protein with an intact
juxtamembrane domain (Figure 2e). We designed four different
gRNAs targeting intron 10 of Pdgfra (designated P4a-d, Figure 1b),
from which three gRNAs were able to generate a fusion gene in
combination with a gRNA targeting Fip1l1 (Figure 2f, the four
different fusions are designated FP9-1 to FP9-4). However, these
fusion proteins were not able to transform Ba/F3 cells (Figure 2g).
These data show that Fip1l1 is dispensable for the transformation
capacities of the Fip1l1–Pdgfrα fusion protein, and that interrup-
tion of the juxtamembrane domain is critical for the activation of
the Fip1l1–Pdgfrα protein. Taken together, these results show that
previously obtained data with overexpression models are valid.
Next, we compared the expression and phosphorylation levels
of Fip1l1–Pdgfrα between the CRISPR/Cas-generated Ba/F3 cells
harboring the endogenous Fip1L1–Pdgfra fusion gene and retro-
virally transduced cells overexpressing FIP1L1–PDGFRA. Retrovirally
transduced cells showed more than 10-fold higher protein
expression and phosphorylation levels of FIP1L1–PDGFRα, as
calculated by ImageJ software. We observed similar expression
and phosphorylation of Stat5, which is a downstream effector of
Fip1l1–Pdgfrα (Figure 2h). When the cells were treated with
100 nM imatinib, the autophosphorylation of Fip1l1–Pdgfrα was
completely inhibited (Figure 2h). Remarkably, the EC50 values
(measured after 24 h exposure to Imatinib) were not significantly
different between the CRISPR/Cas-generated Ba/F3 cells and
retrovirally transduced cells (95% confidence intervals for the
EC50 values shown in Figure 2i). These results show that, despite
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the more than 10-fold difference in protein expression levels, the
sensitivity of the cells to imatinib was not significantly altered.
Overall, these data show that it is feasible to generate fusion
genes in the IL3-dependent Ba/F3 cell line using CRISPR/Cas
genome editing, and that these fusion genes can transform the
cells to IL3-independent growth. We also conclude that no major
differences were observed between Ba/F3 cells overexpressing
FIP1L1–PDGFRA from a retroviral construct and CRISPR/Cas
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Figure 1. Use of CRISPR/Cas genome editing to generate Fip1l1–Pdgfra fusions. (a) Structure of PDGFRα and the FIP1L1-PDGFRα fusion
protein. Formation of the fusion leads to disruption of the JM domain between two tryptophan (W) residues in PDGFRα (TM= transmembrane
domain, JM= juxtamembrane domain). (b) Representation of the Fip1l1 and Pdgfra mouse genes. Exons are indicated by vertical bars. Red
arrows indicate the location of the gRNA target sites in mouse Fip1l1 and Pdgfra. Black arrows indicate homologous sequences of breakpoints
found in patients. (c) Efficiency of the individual gRNAs targeting Fip1l1 and Pdgfra in Ba/F3 cells as determined by Illumina next-generation
sequencing. (d) Growth curve showing the transforming capacities of Ba/F3 cells harboring an endogenous FP1 fusion. Ba/F3 cells harboring a
FP2–FP6 fusion had similar transformation rates (data not shown). Electroporation of only 1 gRNA targeting Fip1l1 or Pdgfra could not
transform the Ba/F3 cells. Cas9 only refers to a vector containing Cas9 without a gRNA sequence. (e) PCR to detect six different gene fusions in
Ba/F3 cells electroporated with a vector containing Cas9 and gRNA sequences targeting Fip1l1 and Pdgfra. Cas9 only refers to a vector
containing Cas9 without a gRNA sequence. (f) Western blot showing six different Fip1l1–Pdgfrα fusion proteins expressed in Ba/F3 cells.
Different breakpoints in Fip1l1 lead to different molecular weights. (g) Sequencing trace showing a fusion between Fip1l1 and Pdgfra in Ba/F3
single cell clones of two different fusion genes (FP1 and FP2). (h) FISH on Ba/F3 cells electroporated with empty vector or with vectors
containing Fip1l1–Pdgfra gRNAs. The white arrow indicates loss of one copy of Chic2, a gene in the deleted region between Fip1l1 and Pdgfra.
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Figure 2. Study of the properties of the Fip1l1–Pdgfrα fusion protein. (a) Structure of the FP7 fusion. Break points are located in Fip1l1 exon 1
and Pdgfra exon 12 (W= tryptophan residue, TM= transmembrane domain, JM= juxtamembrane domain). (b) PCR to detect the FP7 fusion in
Ba/F3 cells. (c) Western blot showing expression of the FP7 fusion protein in Ba/F3 cells after electroporation of gRNAs targeting Fip1l1 exon 1
and Pdgfra exon 12. (d) Growth curve showing the transforming capacities of Ba/F3 cells harboring an endogenous FP7 fusion. (e) Structure of
the FP9 fusion. Break points are located in Fip1l1 exon 9 and Pdgfra exon 11 (W= tryptophan residue, TM= transmembrane domain,
JM= juxtamembrane domain). (f) PCR to detect four different FP9 fusions with four different gRNAs targeting the upstream region of Pdgfra
exon 11. (g) Growth curve of Ba/F3 cells harboring an endogenous FP1 or FP9 fusion. (h) Western blot showing the effects of Imatinib on the
Fip1l1–Pdgfrα fusion protein. Ba/F3 cells harboring an endogenous FP1 fusion (FP1) and Ba/F3 cells expressing a human FIP1L1–PDGFRA
cDNA (FP retro) were treated for 90 min with 0 or 100 nM Imatinib. On the blots showing expression of (p-)Fip1l1–Pdgfra, a 1/10 dilution of FP
retro is shown. Difference in molecular weight of Fip1l1–Pdgfrα is due to differences in molecular weight between the mouse and human
fusion proteins. (i) Dose response curve for Imatinib. EC50 values are represented by 95% confidence intervals.
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engineered cells. The cells equally activated the downstream
effector Stat5, and were equally sensitive to imatinib, despite the
huge differences in protein expression levels. Moreover, previous
data on the mechanism of activation were confirmed in the
CRISPR/Cas engineered cells. Our data demonstrate an important
application of the CRISPR/Cas genome editing tool, which makes it
possible to study the oncogenic properties of activated tyrosine
kinases without the need for ectopic overexpression.
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